Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine in Refractory T-Cell Malignancies
NCT00002970Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 1997
- Primary completion
- Jan 2005
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nelarabine in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by National Cancer Institute. Started Jun 1997; status: completed.
02
Drugs
nelarabine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT00002970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002970.